Quanterix posts $35.0m quarterly revenue and eyes 2027 diagnostic filing for HD-X
Third-quarter sales rose 6.3% sequentially as Lucent AD test volumes doubled, while the company flagged a planned regulatory submission for its HD-X instrument next year.
Quanterix reported third-quarter 2026 revenue of $35.0m on 9 November, a 6.3% increase on the preceding quarter. The company described the result as better than it had expected.
Two commercial indicators stood out. Volumes of its Lucent AD test doubled during the quarter, and bookings at its Accelerator Lab rose. The announcement as reviewed gives no absolute volumes or booking values, and does not specify the period against which the doubling is measured, so the scale of either trend cannot be assessed.
Looking ahead, Quanterix said it intends to introduce new Simoa neurology assays and to file an in vitro diagnostic (IVD) submission for the HD-X platform in 2027. The material available does not name the assays, the intended markets or the regulatory route.
The company also updated its 2026 guidance, but the revised figures were not included in the information reviewed. The quarter follows Quanterix's acquisitions of Emission and Akoya Biosciences; how far either deal contributed to the reported revenue is not stated.
Why it matters
- A 2027 IVD submission for HD-X would mark a step towards regulated clinical use of the platform; the pathway and jurisdictions are still unknown.
- Doubled Lucent AD volumes point to rising uptake of a blood-based neurology test, though without absolute numbers the commercial weight is unclear.
- The revised 2026 guidance and the contribution from the Emission and Akoya deals are undisclosed in the material reviewed, limiting any read on underlying growth.
Company's press release (SEC filing): Quanterix Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
